Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has received a consensus rating of “Hold” from the twenty-two research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $49.21.

A number of research firms recently weighed in on PCRX. Jefferies Group reaffirmed a “buy” rating and set a $59.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Tuesday, October 3rd. Needham & Company LLC decreased their price objective on Pacira Pharmaceuticals from $55.00 to $52.00 and set a “buy” rating for the company in a report on Thursday, October 19th. HC Wainwright reissued a “buy” rating and set a $52.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. Finally, Janney Montgomery Scott lowered Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 price objective for the company. in a report on Thursday, October 26th.

Pacira Pharmaceuticals (NASDAQ PCRX) opened at $44.15 on Monday. Pacira Pharmaceuticals has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. The firm has a market capitalization of $1,820.00, a P/E ratio of -33.70 and a beta of 2.20.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The business had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. During the same period in the prior year, the business earned $0.20 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. analysts anticipate that Pacira Pharmaceuticals will post -0.85 earnings per share for the current year.

In other news, CEO David M. Stack sold 58,885 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the completion of the transaction, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark A. Kronenfeld bought 1,000 shares of Pacira Pharmaceuticals stock in a transaction dated Friday, November 10th. The stock was acquired at an average cost of $41.60 per share, with a total value of $41,600.00. Following the completion of the acquisition, the director now owns 6,795 shares of the company’s stock, valued at $282,672. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 70,075 shares of company stock valued at $2,707,452. 6.60% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in PCRX. Oppenheimer Asset Management Inc. purchased a new position in Pacira Pharmaceuticals in the second quarter valued at approximately $114,000. Cubist Systematic Strategies LLC lifted its position in shares of Pacira Pharmaceuticals by 121.5% during the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after acquiring an additional 1,752 shares in the last quarter. QS Investors LLC purchased a new stake in shares of Pacira Pharmaceuticals during the second quarter worth $157,000. Ameritas Investment Partners Inc. lifted its position in shares of Pacira Pharmaceuticals by 9.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after acquiring an additional 302 shares in the last quarter. Finally, Spectrum Management Group Inc. purchased a new stake in shares of Pacira Pharmaceuticals during the third quarter worth $166,000.

ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Receives Average Rating of “Hold” from Brokerages” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://theolympiareport.com/2017/12/25/pacira-pharmaceuticals-inc-pcrx-receives-average-rating-of-hold-from-brokerages.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.